Online inquiry

IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2622MR)

This product GTTS-WQ2622MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ICOSLG gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001283050.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23308
UniProt ID O75144
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2622MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1468MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ2074MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ3381MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ3630MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ769MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ11745MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ7958MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ14260MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW